Menu
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in =65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.
1800 Bridge Pkwy
Redwood City, California 94065-1164
Phone: 16502510005
www.nevro.com
Publications Show Reductions in Hospital Resource Utilization Associated with 10 kHz TherapySpinal Cord Stimulation for the Treatment of Painful Diabetic Neuropathy and Nonsurgical Refractory Back Pain REDWOOD CITY, Calif., Sept. 18, 2023 /PRNewswire/ — Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, […] The post New Data Demonstrate the Health Economic Benefits of Nevro’s High-Frequency Spinal Cord Stimulation Therapy appeared first on TodaysStocks.com .
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain. Find out why I revise my rating on NVRO stock a hold.
https://www.investing.com/news/pro/nevro-corp-receives-investment-bank-analyst-rating-update-3157961
Evidence Published in Diabetes Research and Clinical Practice Shows 10 kHz Therapy Yields Lasting Pain Relief and Enhances
https://www.investing.com/news/assorted/nevro-announces-new-24month-data-shows-scs-therapy-provides-highly-effective-longterm-relief-from-painful-diabetic-neuropathy-432SI-3155324
Evidence Published in Diabetes Research and Clinical Practice Shows 10 kHz Therapy Yields Lasting Pain Relief and Enhances Health-Related Quality of Life and Sleep REDWOOD CITY, Calif., Aug. 16, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering…
REDWOOD CITY, Calif., Aug. 10, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO) has announced today the launch of HFX Connect in Europe and CE marking of expanded labelling (Painful Diabetic Neuropat…
REDWOOD CITY, Calif., Aug. 10, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO) has announced today the launch of HFX Connect in Europe and CE marking of expanded labelling (Painful Diabetic Neuropathy, PDN and Non-Surgical Back Pain, NSBP) for the HFX SCS system. The latest development from the global medical device company delivering comprehensive, life-changing solutions for the treatment of
The medical device maker saw increased revenue, but earnings lagged estimates.
Pain management company Nevro Corp (NASDAQ: NVRO ) reported Q2 FY23 revenue of $108.8 million, up 4% Y/Y, missing the management guidance of $110 million-$112 million and consensus of $109.33 million . Painful Diabetic Neuropathy (PDN) indication sales of approximately $19.0 million grew 73% . Q2 U.S. permanent implant procedures increased by 8%, while U.S. trial procedures increased by 4%, U.S. PDN trial procedures represented approximately 23% of total U.S. trial volume and grew approximately 64% Y/Y. Adjusted EBITDA was a loss of $3.1 million, compared to a loss of $4.5 million a year ago and the guidance of a loss of